Predicting chemotherapy response in pancreatic cancer using a blood microRNA panel

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PRECEPT is a retrospective, non-interventional analysis using archived pre-treatment plasma from patients with resectable or borderline resectable pancreatic ductal adenocarcinoma who received neoadjuvant FOLFIRINOX or gemcitabine plus nab‑paclitaxel and subsequently underwent curative-intent surgery. Investigators performed exosomal small RNA sequencing to identify candidate microRNAs and will validate selected candidates by qRT-PCR in an independent cohort. The study will correlate pre-treatment miRNA levels with pathologic response (CAP grade or tumor regression score) and explore associations with overall survival and recurrence-free survival. All analyses are performed on existing biospecimens and clinical records without additional interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
* Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
* Availability of pre-treatment plasma samples.
* Underwent curative-intent resection (R0 or R1).

Exclusion Criteria:

* Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
* Non-adenocarcinoma histology.
* Presence of synchronous or multiple primary malignancies.
* Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
* Presence of active inflammatory or autoimmune diseases.

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting

Study contacts

• Principal investigator: Ajay Goel, PhD — City of Hope Medical Center
• Study coordinator: Ajay Goel, PhD
• Email: ajgoel@coh.org
• Phone: 626-218-3452

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC

  This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.

  Recruiting at 10 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Concord, New South Wales and 16 other locations · NCT07678593

• First-in-human test of BLU-924 for KRAS-mutant advanced cancers

  This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.

  Recruiting at 3 sites Phase 1/2 Blueprint Medicines Corporation · Sarasota, Florida and 15 other locations · NCT07629960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.